NEXTECH INVEST LTD
Q4 2024 Form 13-F
ZURICH
CIK 0001911010
· CRD 322629
· Exempt reporting adviser
$616.4M Reported Value Total
Exempt Reporting Adviser
nextechinvest.com
Source: Form ADV filed 2026-03-27
Reported value
$616.4M
Quarter over quarter
-21.2%
Holdings
15
Top-10 concentration
93.6%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Marco Weibel
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2024 13F record
Q4 2024 13F filing summary
| Period of report | December 31, 2024 |
|---|---|
| Filed | February 14, 2025 |
| Form | 13F-HR |
| Reported value | $616.4M |
| Positions | 15 |
| Change in reported value | -13.5% |
| New positions | 0 |
| Exited positions | 0 |
| Position turnover | 0.0% |
| Top-10 concentration | 93.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2024 13F
Filed Feb 14, 2025
|
15 | $616.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $712.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $594.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $630.8M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
11 | $536.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
14 | $330.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
13 | $294.2M |
|
Q1 2023 13F
Filed May 12, 2023
|
12 | $239.6M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
14 | $251.4M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
14 | $309.6M |
|
Q2 2022 13F
Filed Aug 1, 2022
|
14 | $296.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
14 | $350.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
11 | $379.6M |
Top 15 holdings · Q4 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | $332.5M | 53.94% |
| 2 | TYRA TYRA BIOSCIENCES INC | $56.4M | 9.15% |
| 3 | ORIC ORIC PHARMACEUTICALS INC | $42.7M | 6.92% |
| 4 | CRGX CARGO THERAPEUTICS INC | $38.1M | 6.18% |
| 5 | ARVN ARVINAS INC | $27.0M | 4.38% |
| 6 | MRSN MERSANA THERAPEUTICS INC | $17.3M | 2.8% |
| 7 | TNGX TANGO THERAPEUTICS INC | $17.1M | 2.77% |
| 8 | ZYME ZYMEWORKS INC | $16.3M | 2.65% |
| 9 | RLAY RELAY THERAPEUTICS INC | $15.8M | 2.57% |
| 10 | CGEM CULLINAN ONCOLOGY INC | $13.9M | 2.25% |
| 11 | ALMS ALUMIS INC | $11.6M | 1.88% |
| 12 | SPRY ARS PHARMACEUTICALS INC | $9.9M | 1.6% |
| 13 | CNTX CONTEXT THERAPEUTICS INC | $7.8M | 1.26% |
| 14 | SLN SILENCE THERAPEUTICS PLC | $6.6M | 1.06% |
| 15 | BOLD BOUNDLESS BIO INC | $3.6M | 0.58% |
Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.